JP2012532887A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012532887A5 JP2012532887A5 JP2012519763A JP2012519763A JP2012532887A5 JP 2012532887 A5 JP2012532887 A5 JP 2012532887A5 JP 2012519763 A JP2012519763 A JP 2012519763A JP 2012519763 A JP2012519763 A JP 2012519763A JP 2012532887 A5 JP2012532887 A5 JP 2012532887A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- alkyl
- channel
- receptor
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 24
- 238000000034 method Methods 0.000 claims 17
- 125000000217 alkyl group Chemical group 0.000 claims 12
- 108020003175 receptors Proteins 0.000 claims 9
- 102000005962 receptors Human genes 0.000 claims 9
- -1 N-methyl-procaine Chemical compound 0.000 claims 8
- 125000003342 alkenyl group Chemical group 0.000 claims 8
- 125000000304 alkynyl group Chemical group 0.000 claims 8
- 125000004404 heteroalkyl group Chemical group 0.000 claims 8
- 239000012190 activator Substances 0.000 claims 7
- 210000000929 nociceptor Anatomy 0.000 claims 7
- 108091008700 nociceptors Proteins 0.000 claims 7
- 125000002877 alkyl aryl group Chemical group 0.000 claims 6
- QTGIAADRBBLJGA-UHFFFAOYSA-N Articaine Chemical compound CCCNC(C)C(=O)NC=1C(C)=CSC=1C(=O)OC QTGIAADRBBLJGA-UHFFFAOYSA-N 0.000 claims 5
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims 5
- 229960003831 articaine Drugs 0.000 claims 5
- BLZVCIGGICSWIG-UHFFFAOYSA-N 2-aminoethoxydiphenylborane Chemical compound C=1C=CC=CC=1B(OCCN)C1=CC=CC=C1 BLZVCIGGICSWIG-UHFFFAOYSA-N 0.000 claims 4
- 108091006146 Channels Proteins 0.000 claims 4
- 150000001412 amines Chemical class 0.000 claims 4
- 150000001450 anions Chemical class 0.000 claims 4
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 claims 4
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 claims 4
- 229960004919 procaine Drugs 0.000 claims 4
- 229960002372 tetracaine Drugs 0.000 claims 4
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 claims 4
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 claims 3
- ZOJBYZNEUISWFT-UHFFFAOYSA-N allyl isothiocyanate Chemical compound C=CCN=C=S ZOJBYZNEUISWFT-UHFFFAOYSA-N 0.000 claims 3
- 229960003150 bupivacaine Drugs 0.000 claims 3
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical group COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 229960001807 prilocaine Drugs 0.000 claims 3
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 claims 3
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims 3
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 claims 2
- JVJFIQYAHPMBBX-UHFFFAOYSA-N 4-hydroxynonenal Chemical compound CCCCCC(O)C=CC=O JVJFIQYAHPMBBX-UHFFFAOYSA-N 0.000 claims 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 2
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 claims 2
- MVVPIAAVGAWJNQ-DOFZRALJSA-N Arachidonoyl dopamine Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCC1=CC=C(O)C(O)=C1 MVVPIAAVGAWJNQ-DOFZRALJSA-N 0.000 claims 2
- VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 claims 2
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 claims 2
- DKLKMKYDWHYZTD-UHFFFAOYSA-N Hexylcaine Chemical compound C=1C=CC=CC=1C(=O)OC(C)CNC1CCCCC1 DKLKMKYDWHYZTD-UHFFFAOYSA-N 0.000 claims 2
- 101000764872 Homo sapiens Transient receptor potential cation channel subfamily A member 1 Proteins 0.000 claims 2
- 229920001144 Hydroxy alpha sanshool Polymers 0.000 claims 2
- LHFKHAVGGJJQFF-UEOYEZOQSA-N Hydroxy-alpha-sanshool Chemical compound C\C=C\C=C\C=C/CC\C=C\C(=O)NCC(C)(C)O LHFKHAVGGJJQFF-UEOYEZOQSA-N 0.000 claims 2
- 108090000862 Ion Channels Proteins 0.000 claims 2
- 102000004310 Ion Channels Human genes 0.000 claims 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims 2
- OPZKBPQVWDSATI-KHPPLWFESA-N N-Vanillyloleamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)NCC1=CC=C(O)C(OC)=C1 OPZKBPQVWDSATI-KHPPLWFESA-N 0.000 claims 2
- QQBPLXNESPTPNU-KTKRTIGZSA-N N-oleoyldopamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)NCCC1=CC=C(O)C(O)=C1 QQBPLXNESPTPNU-KTKRTIGZSA-N 0.000 claims 2
- 208000007920 Neurogenic Inflammation Diseases 0.000 claims 2
- YQKAVWCGQQXBGW-UHFFFAOYSA-N Piperocaine Chemical compound CC1CCCCN1CCCOC(=O)C1=CC=CC=C1 YQKAVWCGQQXBGW-UHFFFAOYSA-N 0.000 claims 2
- 102000003610 TRPM8 Human genes 0.000 claims 2
- 102100026186 Transient receptor potential cation channel subfamily A member 1 Human genes 0.000 claims 2
- 101150111302 Trpm8 gene Proteins 0.000 claims 2
- ROFVXGGUISEHAM-UHFFFAOYSA-N URB597 Chemical compound NC(=O)C1=CC=CC(C=2C=C(OC(=O)NC3CCCCC3)C=CC=2)=C1 ROFVXGGUISEHAM-UHFFFAOYSA-N 0.000 claims 2
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 claims 2
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 claims 2
- FADFGCOCHHNRHF-VAWYXSNFSA-N [10]-Shogaol Chemical compound CCCCCCCCC\C=C\C(=O)CCC1=CC=C(O)C(OC)=C1 FADFGCOCHHNRHF-VAWYXSNFSA-N 0.000 claims 2
- 229960005274 benzocaine Drugs 0.000 claims 2
- 229940105270 carbocaine Drugs 0.000 claims 2
- 229960002023 chloroprocaine Drugs 0.000 claims 2
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 claims 2
- 229960001747 cinchocaine Drugs 0.000 claims 2
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 claims 2
- PFRGXCVKLLPLIP-UHFFFAOYSA-N diallyl disulfide Chemical compound C=CCSSCC=C PFRGXCVKLLPLIP-UHFFFAOYSA-N 0.000 claims 2
- OWQIUQKMMPDHQQ-UHFFFAOYSA-N dimethocaine Chemical compound CCN(CC)CC(C)(C)COC(=O)C1=CC=C(N)C=C1 OWQIUQKMMPDHQQ-UHFFFAOYSA-N 0.000 claims 2
- 229950010160 dimethocaine Drugs 0.000 claims 2
- 229960003976 etidocaine Drugs 0.000 claims 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 229960005388 hexylcaine Drugs 0.000 claims 2
- LHFKHAVGGJJQFF-UHFFFAOYSA-N hydroxyl-alpha-sanshool Natural products CC=CC=CC=CCCC=CC(=O)NCC(C)(C)O LHFKHAVGGJJQFF-UHFFFAOYSA-N 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 229960004288 levobupivacaine Drugs 0.000 claims 2
- LEBVLXFERQHONN-INIZCTEOSA-N levobupivacaine Chemical compound CCCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-INIZCTEOSA-N 0.000 claims 2
- 229960004194 lidocaine Drugs 0.000 claims 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 claims 2
- 229960002409 mepivacaine Drugs 0.000 claims 2
- OGRGWTXWAZBJKF-JXWJAAHMSA-N phorbol 12-phenylacetate 13-acetate 20-homovanillate Chemical compound C1=C(O)C(OC)=CC(CC(=O)OCC=2C[C@]3(O)C(=O)C(C)=C[C@H]3[C@@]3(O)[C@H](C)[C@@H](OC(=O)CC=4C=CC=CC=4)[C@@]4(OC(C)=O)C(C)(C)[C@H]4[C@@H]3C=2)=C1 OGRGWTXWAZBJKF-JXWJAAHMSA-N 0.000 claims 2
- 229960001045 piperocaine Drugs 0.000 claims 2
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 claims 2
- 229960001549 ropivacaine Drugs 0.000 claims 2
- GOZBHBFUQHMKQB-UHFFFAOYSA-N trimecaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=C(C)C=C1C GOZBHBFUQHMKQB-UHFFFAOYSA-N 0.000 claims 2
- 229950002569 trimecaine Drugs 0.000 claims 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical group CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims 1
- BUJAGSGYPOAWEI-SECBINFHSA-N (2r)-2-amino-n-(2,6-dimethylphenyl)propanamide Chemical compound C[C@@H](N)C(=O)NC1=C(C)C=CC=C1C BUJAGSGYPOAWEI-SECBINFHSA-N 0.000 claims 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 claims 1
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 claims 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 claims 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 claims 1
- MRDJEHJOSCNEAJ-UHFFFAOYSA-N 1-[(4-tert-butylphenyl)methyl]-3-[(4-hydroxy-3-methoxyphenyl)methyl]thiourea Chemical compound C1=C(O)C(OC)=CC(CNC(=S)NCC=2C=CC(=CC=2)C(C)(C)C)=C1 MRDJEHJOSCNEAJ-UHFFFAOYSA-N 0.000 claims 1
- ZIOZYRSDNLNNNJ-LQWMCKPYSA-N 12(S)-HPETE Chemical compound CCCCC\C=C/C[C@H](OO)\C=C\C=C/C\C=C/CCCC(O)=O ZIOZYRSDNLNNNJ-LQWMCKPYSA-N 0.000 claims 1
- XPYXSZDENRDLKD-UHFFFAOYSA-N 2-octylguanidine Chemical compound CCCCCCCCN=C(N)N XPYXSZDENRDLKD-UHFFFAOYSA-N 0.000 claims 1
- AWJJLYZBWRIBCZ-UGTJMOTHSA-N 3'-O-(4-Benzoyl)benzoyl ATP Chemical compound O([C@@H]1[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]([C@@H]1O)N1C=2N=CN=C(C=2N=C1)N)C(=O)C(C=C1)=CC=C1C(=O)C1=CC=CC=C1 AWJJLYZBWRIBCZ-UGTJMOTHSA-N 0.000 claims 1
- 125000006185 3,4-dimethyl benzyl group Chemical group [H]C1=C(C([H])=C(C(=C1[H])C([H])([H])[H])C([H])([H])[H])C([H])([H])* 0.000 claims 1
- IITCVPTZKLXSKQ-ZSVIJTOTSA-N 6'-iodoresiniferatoxin Chemical compound C1=C(O)C(OC)=CC(CC(=O)OCC=2C[C@]3(O)C(=O)C(C)=C[C@H]3[C@@]34[C@H](C)C[C@@]5(OC(O4)(CC=4C=CC=CC=4)O[C@@H]5[C@@H]3C=2)C(C)=C)=C1I IITCVPTZKLXSKQ-ZSVIJTOTSA-N 0.000 claims 1
- XJGFWWJLMVZSIG-UHFFFAOYSA-N 9-aminoacridine Chemical compound C1=CC=C2C(N)=C(C=CC=C3)C3=NC2=C1 XJGFWWJLMVZSIG-UHFFFAOYSA-N 0.000 claims 1
- 102100027782 ATP synthase-coupling factor 6, mitochondrial Human genes 0.000 claims 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 claims 1
- 108010078791 Carrier Proteins Proteins 0.000 claims 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 claims 1
- 239000005770 Eugenol Substances 0.000 claims 1
- 208000007882 Gastritis Diseases 0.000 claims 1
- 239000005792 Geraniol Substances 0.000 claims 1
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 claims 1
- 101000936965 Homo sapiens ATP synthase-coupling factor 6, mitochondrial Proteins 0.000 claims 1
- 102000003820 Lipoxygenases Human genes 0.000 claims 1
- 108090000128 Lipoxygenases Proteins 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims 1
- KCLANYCVBBTKTO-UHFFFAOYSA-N Proparacaine Chemical compound CCCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1N KCLANYCVBBTKTO-UHFFFAOYSA-N 0.000 claims 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 102000002294 Purinergic P2X Receptors Human genes 0.000 claims 1
- 108010000836 Purinergic P2X Receptors Proteins 0.000 claims 1
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 claims 1
- 241001303601 Rosacea Species 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010042496 Sunburn Diseases 0.000 claims 1
- 102000003566 TRPV1 Human genes 0.000 claims 1
- 108010025083 TRPV1 receptor Proteins 0.000 claims 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 claims 1
- 101150016206 Trpv1 gene Proteins 0.000 claims 1
- WSINRQSTSKCAEN-UGTJMOTHSA-N [(2r,3r,4r,5r)-2-(6-aminopurin-9-yl)-4-hydroxy-5-[[hydroxy-[hydroxy(phosphonooxy)phosphoryl]oxyphosphoryl]oxymethyl]oxolan-3-yl] 4-benzoylbenzoate Chemical compound O([C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C=2N=CN=C(C=2N=C1)N)C(=O)C(C=C1)=CC=C1C(=O)C1=CC=CC=C1 WSINRQSTSKCAEN-UGTJMOTHSA-N 0.000 claims 1
- QYUXPWDVDMSTKR-UHFFFAOYSA-O [2-(2,6-dimethylanilino)-2-oxoethyl]-trimethylammonium Chemical compound CC1=CC=CC(C)=C1NC(=O)C[N+](C)(C)C QYUXPWDVDMSTKR-UHFFFAOYSA-O 0.000 claims 1
- KDYVIORLSJSMTG-UHFFFAOYSA-N [2-[(3,4-dimethylphenyl)methyl]-3-[(4-hydroxy-3-methoxyphenyl)methylcarbamothioylamino]propyl] 2,2-dimethylpropanoate Chemical compound C1=C(O)C(OC)=CC(CNC(=S)NCC(COC(=O)C(C)(C)C)CC=2C=C(C)C(C)=CC=2)=C1 KDYVIORLSJSMTG-UHFFFAOYSA-N 0.000 claims 1
- XNOBOKJVOTYSJV-KQYNXXCUSA-N [[(2r,3s,4r,5r)-5-(6-amino-2-methylsulfanylpurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C12=NC(SC)=NC(N)=C2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XNOBOKJVOTYSJV-KQYNXXCUSA-N 0.000 claims 1
- AYJBWCXXFCSXNE-UHFFFAOYSA-N [hydroxy(phosphonooxy)phosphinothioyl] dihydrogen phosphate Chemical compound OP(O)(=O)OP(O)(=S)OP(O)(O)=O AYJBWCXXFCSXNE-UHFFFAOYSA-N 0.000 claims 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 1
- 206010069351 acute lung injury Diseases 0.000 claims 1
- 235000016720 allyl isothiocyanate Nutrition 0.000 claims 1
- 229960001441 aminoacridine Drugs 0.000 claims 1
- LGEQQWMQCRIYKG-DOFZRALJSA-N anandamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO LGEQQWMQCRIYKG-DOFZRALJSA-N 0.000 claims 1
- 230000001773 anti-convulsant effect Effects 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 239000001961 anticonvulsive agent Substances 0.000 claims 1
- 229960003965 antiepileptics Drugs 0.000 claims 1
- LGEQQWMQCRIYKG-UHFFFAOYSA-N arachidonic acid ethanolamide Natural products CCCCCC=CCC=CCC=CCC=CCCCC(=O)NCCO LGEQQWMQCRIYKG-UHFFFAOYSA-N 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- FYJJXENSONZJRG-UHFFFAOYSA-N bencyclane Chemical compound C=1C=CC=CC=1CC1(OCCCN(C)C)CCCCCC1 FYJJXENSONZJRG-UHFFFAOYSA-N 0.000 claims 1
- 229960000945 bencyclane Drugs 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- AAQOQKQBGPPFNS-UHFFFAOYSA-N bretylium Chemical compound CC[N+](C)(C)CC1=CC=CC=C1Br AAQOQKQBGPPFNS-UHFFFAOYSA-N 0.000 claims 1
- 229960002624 bretylium tosilate Drugs 0.000 claims 1
- 229960002504 capsaicin Drugs 0.000 claims 1
- 235000017663 capsaicin Nutrition 0.000 claims 1
- 229960000623 carbamazepine Drugs 0.000 claims 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 claims 1
- 229960005233 cineole Drugs 0.000 claims 1
- 229940117916 cinnamic aldehyde Drugs 0.000 claims 1
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 claims 1
- 239000010630 cinnamon oil Substances 0.000 claims 1
- 239000010634 clove oil Substances 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- 238000013270 controlled release Methods 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- 201000003146 cystitis Diseases 0.000 claims 1
- 239000003344 environmental pollutant Substances 0.000 claims 1
- 229960002217 eugenol Drugs 0.000 claims 1
- SMANXXCATUTDDT-QPJJXVBHSA-N flunarizine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C\C=C\C=2C=CC=CC=2)CC1 SMANXXCATUTDDT-QPJJXVBHSA-N 0.000 claims 1
- 229960000326 flunarizine Drugs 0.000 claims 1
- 229940113087 geraniol Drugs 0.000 claims 1
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 claims 1
- 235000002780 gingerol Nutrition 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 1
- WPFVBOQKRVRMJB-UHFFFAOYSA-N hydroxycitronellal Chemical compound O=CCC(C)CCCC(C)(C)O WPFVBOQKRVRMJB-UHFFFAOYSA-N 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007915 intraurethral administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 229960001848 lamotrigine Drugs 0.000 claims 1
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 claims 1
- 229930007744 linalool Natural products 0.000 claims 1
- 229940041616 menthol Drugs 0.000 claims 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 claims 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims 1
- VLPIATFUUWWMKC-UHFFFAOYSA-N mexiletine Chemical compound CC(N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-UHFFFAOYSA-N 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000008164 mustard oil Substances 0.000 claims 1
- 230000003533 narcotic effect Effects 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- OPZKBPQVWDSATI-UHFFFAOYSA-N oleoyl vanillylamide Natural products CCCCCCCCC=CCCCCCCCC(=O)NCC1=CC=C(O)C(OC)=C1 OPZKBPQVWDSATI-UHFFFAOYSA-N 0.000 claims 1
- 229950010717 olvanil Drugs 0.000 claims 1
- GVEAYVLWDAFXET-XGHATYIMSA-N pancuronium Chemical compound C[N+]1([C@@H]2[C@@H](OC(C)=O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(C)CCCCC2)CCCCC1 GVEAYVLWDAFXET-XGHATYIMSA-N 0.000 claims 1
- 229960005457 pancuronium Drugs 0.000 claims 1
- 229960005489 paracetamol Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- IMACFCSSMIZSPP-UHFFFAOYSA-N phenacyl chloride Chemical compound ClCC(=O)C1=CC=CC=C1 IMACFCSSMIZSPP-UHFFFAOYSA-N 0.000 claims 1
- 229960002036 phenytoin Drugs 0.000 claims 1
- 235000019100 piperine Nutrition 0.000 claims 1
- MXXWOMGUGJBKIW-YPCIICBESA-N piperine Chemical compound C=1C=C2OCOC2=CC=1/C=C/C=C/C(=O)N1CCCCC1 MXXWOMGUGJBKIW-YPCIICBESA-N 0.000 claims 1
- 229940075559 piperine Drugs 0.000 claims 1
- WVWHRXVVAYXKDE-UHFFFAOYSA-N piperine Natural products O=C(C=CC=Cc1ccc2OCOc2c1)C3CCCCN3 WVWHRXVVAYXKDE-UHFFFAOYSA-N 0.000 claims 1
- 231100000719 pollutant Toxicity 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 229960003981 proparacaine Drugs 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 229960001404 quinidine Drugs 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 229960004181 riluzole Drugs 0.000 claims 1
- 201000004700 rosacea Diseases 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 239000003491 tear gas Substances 0.000 claims 1
- 229960002872 tocainide Drugs 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- OAHWPNUPCSDOGU-UHFFFAOYSA-N trans-10-shogaol Natural products CCCCCCCCCC=CC(=O)CCc1ccc(O)c(CO)c1 OAHWPNUPCSDOGU-UHFFFAOYSA-N 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 claims 1
- 208000000143 urethritis Diseases 0.000 claims 1
- 239000009637 wintergreen oil Substances 0.000 claims 1
- WZQQAERTDSSFKU-NXGXIAAHSA-N CC(C)=CCC/C(/C)=C/CC/C(/C)=C/C[N](C)(C)C Chemical compound CC(C)=CCC/C(/C)=C/CC/C(/C)=C/C[N](C)(C)C WZQQAERTDSSFKU-NXGXIAAHSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22451209P | 2009-07-10 | 2009-07-10 | |
| US61/224,512 | 2009-07-10 | ||
| PCT/US2010/041537 WO2011006073A1 (en) | 2009-07-10 | 2010-07-09 | Permanently charged sodium and calcium channel blockers as anti-inflammatory agents |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017086446A Division JP6530005B2 (ja) | 2009-07-10 | 2017-04-25 | 抗炎症剤としての恒久的に荷電したナトリウムおよびカルシウムチャンネルブロッカー |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012532887A JP2012532887A (ja) | 2012-12-20 |
| JP2012532887A5 true JP2012532887A5 (enExample) | 2013-08-29 |
| JP6205133B2 JP6205133B2 (ja) | 2017-09-27 |
Family
ID=43429565
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012519763A Expired - Fee Related JP6205133B2 (ja) | 2009-07-10 | 2010-07-09 | 抗炎症剤としての恒久的に荷電したナトリウムおよびカルシウムチャンネルブロッカー |
| JP2017086446A Expired - Fee Related JP6530005B2 (ja) | 2009-07-10 | 2017-04-25 | 抗炎症剤としての恒久的に荷電したナトリウムおよびカルシウムチャンネルブロッカー |
| JP2019091784A Active JP6845280B2 (ja) | 2009-07-10 | 2019-05-15 | 抗炎症剤としての恒久的に荷電したナトリウムおよびカルシウムチャンネルブロッカー |
| JP2021028224A Pending JP2021098713A (ja) | 2009-07-10 | 2021-02-25 | 抗炎症剤としての恒久的に荷電したナトリウムおよびカルシウムチャンネルブロッカー |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017086446A Expired - Fee Related JP6530005B2 (ja) | 2009-07-10 | 2017-04-25 | 抗炎症剤としての恒久的に荷電したナトリウムおよびカルシウムチャンネルブロッカー |
| JP2019091784A Active JP6845280B2 (ja) | 2009-07-10 | 2019-05-15 | 抗炎症剤としての恒久的に荷電したナトリウムおよびカルシウムチャンネルブロッカー |
| JP2021028224A Pending JP2021098713A (ja) | 2009-07-10 | 2021-02-25 | 抗炎症剤としての恒久的に荷電したナトリウムおよびカルシウムチャンネルブロッカー |
Country Status (7)
| Country | Link |
|---|---|
| US (5) | US20120172429A1 (enExample) |
| EP (3) | EP2451944A4 (enExample) |
| JP (4) | JP6205133B2 (enExample) |
| CN (1) | CN102725401A (enExample) |
| AU (4) | AU2010271269B2 (enExample) |
| CA (2) | CA2767646C (enExample) |
| WO (1) | WO2011006073A1 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010510227A (ja) | 2006-11-20 | 2010-04-02 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | 痛みおよび痒みの治療方法、組成物およびキット |
| JP6205133B2 (ja) * | 2009-07-10 | 2017-09-27 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 抗炎症剤としての恒久的に荷電したナトリウムおよびカルシウムチャンネルブロッカー |
| US20130203715A1 (en) * | 2010-07-20 | 2013-08-08 | Pulmatrix, Inc. | Use of trp channel agonists to treat infections |
| US20130164338A1 (en) | 2010-08-30 | 2013-06-27 | Pulmatrix, Inc. | Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder |
| CA3086367A1 (en) | 2010-09-29 | 2012-04-05 | Pulmatrix Operating Company, Inc. | Monovalent metal cation dry powders for inhalation |
| US20140031341A1 (en) * | 2010-12-22 | 2014-01-30 | Universitat Munster | Modulators and methods for the treatment of rosacea |
| CA2822723A1 (en) * | 2010-12-22 | 2012-06-28 | Galderma Research & Development | Modulators of trpa1 for the treatment of rosacea |
| US8865741B2 (en) | 2011-02-18 | 2014-10-21 | Asana Biosciences, Llc | Aminoindane compounds and use thereof in treating pain |
| EP2771320B1 (en) | 2011-10-24 | 2016-06-22 | Endo Pharmaceuticals Inc. | Cyclohexylamines |
| WO2013141202A1 (ja) * | 2012-03-21 | 2013-09-26 | 独立行政法人国立精神・神経医療研究センター | 筋増加剤、及び筋増加物質のスクリーニング方法 |
| WO2014028675A1 (en) | 2012-08-15 | 2014-02-20 | Endo Pharmaceuticals Inc. | Use of aminoindane compounds in treating overactive bladder and interstitial cystitis |
| CN111557432B (zh) | 2013-02-08 | 2023-08-04 | 通用磨坊公司 | 低钠食品 |
| AU2014248455B2 (en) | 2013-04-01 | 2018-12-06 | Pulmatrix Operating Company, Inc. | Tiotropium dry powders |
| US20160096815A1 (en) | 2013-05-23 | 2016-04-07 | Kinki University | T-type calcium channel inhibitor |
| JP2016524609A (ja) * | 2013-05-24 | 2016-08-18 | ネステク ソシエテ アノニム | メントール及び／又はイシリンを用いるうつ病の処置又は予防 |
| JP2016520588A (ja) * | 2013-05-24 | 2016-07-14 | ネステク ソシエテ アノニム | メントール、リナロール及び／又はイシリンを用いる脳外傷及び卒中からの非炎症性ニューロン傷害の処置又は予防 |
| WO2015051336A1 (en) | 2013-10-03 | 2015-04-09 | David Wise | Compositions and methods for treating pelvic pain and other conditions |
| ES2926494T3 (es) | 2015-03-26 | 2022-10-26 | Sen Jam Pharmaceutical Llc | Combinación de naproxeno y fexofenadina para inhibir los síntomas asociados con veisalgia |
| RU2018107695A (ru) | 2015-08-03 | 2019-09-05 | Президент Энд Феллоуз Оф Гарвард Колледж | Заряженные блокаторы ионных каналов и способы их применения |
| CN106214670B (zh) * | 2016-07-25 | 2020-12-29 | 上海璃道医药科技有限公司 | 酰胺类药物的用途 |
| CN106220562B (zh) * | 2016-07-29 | 2019-10-01 | 上海璃道医药科技有限公司 | 两种喹啉环类药物的新用途 |
| CN106892875B (zh) * | 2016-11-11 | 2018-03-02 | 杭州唯铂莱生物科技有限公司 | 钙离子通道阻滞剂化合物及其制备方法和应用 |
| WO2019173394A1 (en) | 2018-03-05 | 2019-09-12 | Wylder Nation Foundation | Compositions and methods for activating signaling through the cb1 cannabinoid receptor for treating and preventing diseases and disorders characterized by abnormal cellular accumulation of sphingolipids such as sphingomyelin |
| WO2019183470A2 (en) | 2018-03-22 | 2019-09-26 | Incarda Therapeutics, Inc. | A novel method to slow ventricular rate |
| CN108467337B (zh) * | 2018-04-23 | 2020-12-15 | 中国科学院烟台海岸带研究所 | 一种倍半萜烯醇类化合物及其制备和应用 |
| CN108324685A (zh) * | 2018-04-28 | 2018-07-27 | 武汉田田药业有限公司 | 一种盐酸氟桂利嗪口服溶液的生产工艺 |
| US12138274B2 (en) | 2018-11-08 | 2024-11-12 | Board Of Regents Of The University Of Nebraska | Compositions and methods for the treatment of peripheral artery disease and cardiopulmonary diseases |
| JP7692834B2 (ja) | 2019-03-11 | 2025-06-16 | ノシオン セラピューティクス，インコーポレイテッド | 荷電したイオンチャンネル遮断薬および使用方法 |
| US10786485B1 (en) | 2019-03-11 | 2020-09-29 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| US10780083B1 (en) | 2019-03-11 | 2020-09-22 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| BR112021017809A2 (pt) | 2019-03-11 | 2021-11-23 | Nocion Therapeutics Inc | Bloqueadores de canais iônicos substituídos por éster e métodos para uso |
| BR112021017772A2 (pt) | 2019-03-11 | 2021-11-16 | Nocion Therapeutics Inc | Bloqueadores de canais de íons carregados e métodos para uso |
| US20230346805A1 (en) | 2019-07-31 | 2023-11-02 | Journey Medical Corporation | Compositions and methods and uses thereof |
| US11020384B2 (en) | 2019-08-01 | 2021-06-01 | Incarda Therapeutics, Inc. | Antiarrhythmic formulation |
| AU2020380118A1 (en) | 2019-11-06 | 2022-05-19 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| JP7513713B2 (ja) | 2019-11-06 | 2024-07-09 | ノシオン セラピューティクス，インコーポレイテッド | 荷電したイオンチャンネル遮断薬および使用方法 |
| BR112022017801A2 (pt) | 2020-03-11 | 2022-10-25 | Nocion Therapeutics Inc | Bloqueadores de canais de íons carregados e métodos para uso |
| US12162851B2 (en) | 2020-03-11 | 2024-12-10 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| WO2023064489A1 (en) * | 2021-10-14 | 2023-04-20 | Galileo Biosystems, Inc. | Aryl hydrocarbon receptor (ahr) modulators and therapeutic uses thereof |
| CA3257661A1 (en) * | 2022-05-31 | 2023-12-07 | Vivasor Inc | METHOD FOR TREATING AN INFLAMMATORY DYSFUNCTION OF THE ORAL MUCOSA |
| CN114853630B (zh) * | 2022-06-07 | 2023-06-27 | 温州医科大学 | 一种2,6-二苯亚甲基环己酮肟类化合物及其制备方法和应用 |
Family Cites Families (125)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE151036C (enExample) | ||||
| DE150423C (enExample) | ||||
| US812554A (en) | 1905-11-08 | 1906-02-13 | Hoechst Ag | Alkamin esters of para-aminobenzoic acid. |
| US1889645A (en) | 1930-12-22 | 1932-11-29 | Winthrop Chem Co Inc | Beta-dimethylaminoethyl ester of para-butylamino-benzoic acid |
| US2441498A (en) | 1943-07-15 | 1948-05-11 | Astra Apotekarnes Kem Fab | Alkyl glycinanilides |
| US2689248A (en) | 1950-06-17 | 1954-09-14 | Sterling Drug Inc | Tertiary-aminoalkyl 4-amino-2-alkoxybenzoates and their synth esis |
| US2799679A (en) | 1955-04-28 | 1957-07-16 | Bofors Ab | Process of preparing amides of heterocyclic carboxylic acids |
| US2883271A (en) | 1956-11-23 | 1959-04-21 | Phillips Petroleum Co | Safety system for combustion process |
| US2955111A (en) | 1957-01-28 | 1960-10-04 | Bofors Ab | Synthesis of n-alkyl-piperidine and n-alkyl-pyrrolidine-alpha-carboxylic acid amides |
| US3160662A (en) | 1957-06-26 | 1964-12-08 | Astra Apotekarnes Kem Fab | Lower alkylaminoacyl amide anesthetics |
| NL281394A (enExample) | 1961-07-25 | |||
| DE1251764B (de) | 1965-08-18 | 1967-10-12 | C H Boehnnger Sohn Ingelheim/ Rhein | Verfahren zur Herstellung von antimikrobiell wirksamen 12 3,4-Tetra hydro 9 -ammo acridmiumverbmdungen |
| US3812147A (en) | 1970-12-22 | 1974-05-21 | Astra Pharma Prod | Acylxylidide local anaesthetics |
| US3931195A (en) | 1971-03-03 | 1976-01-06 | Mead Johnson & Company | Substituted piperidines |
| BE786875A (fr) | 1971-07-28 | 1973-01-29 | Astra Pharma Prod | Amide, methode pour sa preparation et ses compositions therapeutiques |
| US3773939A (en) | 1971-11-24 | 1973-11-20 | Janssen Pharmaceutica Nv | N-arallyl-n'-aralkyl piperazine pharmaceutical compositions |
| US4069309A (en) | 1972-09-19 | 1978-01-17 | Avon Products, Inc. | Cationic skin substantive sunscreen composition and method |
| US3900481A (en) | 1974-04-01 | 1975-08-19 | Riker Laboratories Inc | Derivatives of pyrrolidine and piperidine |
| CS195321B2 (en) | 1975-12-23 | 1980-01-31 | Ciba Geigy Ag | Plant growth suppressing agents |
| US4070347A (en) | 1976-08-16 | 1978-01-24 | Alza Corporation | Poly(orthoester) co- and homopolymers and poly(orthocarbonate) co- and homopolymers having carbonyloxy functionality |
| DE2915250A1 (de) | 1979-04-14 | 1980-10-30 | Basf Ag | Salze von alpha -aminoacetaniliden |
| US4293539A (en) | 1979-09-12 | 1981-10-06 | Eli Lilly And Company | Controlled release formulations and method of treatment |
| US4877805A (en) | 1985-07-26 | 1989-10-31 | Kligman Albert M | Methods for treatment of sundamaged human skin with retinoids |
| US4757128A (en) | 1986-08-01 | 1988-07-12 | Massachusetts Institute Of Technology | High molecular weight polyanhydride and preparation thereof |
| US5169637A (en) | 1983-03-24 | 1992-12-08 | The Liposome Company, Inc. | Stable plurilamellar vesicles |
| AU560367B2 (en) | 1983-08-01 | 1987-04-02 | Astra Lakemedel Aktiebolag | L-n-n-propylpipecolic acid-2,6-xylidide and method for preparing the same |
| CA1237671A (en) | 1983-08-01 | 1988-06-07 | Michael W. Fountain | Enhancement of pharmaceutical activity |
| US5409704A (en) | 1985-06-26 | 1995-04-25 | The Liposome Company, Inc. | Liposomes comprising aminoglycoside phosphates and methods of production and use |
| US4975282A (en) | 1985-06-26 | 1990-12-04 | The Liposome Company, Inc. | Multilamellar liposomes having improved trapping efficiencies |
| US5023087A (en) | 1986-02-10 | 1991-06-11 | Liposome Technology, Inc. | Efficient method for preparation of prolonged release liposome-based drug delivery system |
| IE60901B1 (en) | 1986-08-21 | 1994-08-24 | Vestar Inc | Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics |
| US5049388A (en) | 1986-11-06 | 1991-09-17 | Research Development Foundation | Small particle aerosol liposome and liposome-drug combinations for medical use |
| CA1319144C (en) | 1986-11-14 | 1993-06-15 | Quirico Branca | Tetrahydronaphthalene derivatives |
| US5032582A (en) | 1987-02-27 | 1991-07-16 | Liposome Technology, Inc. | Method for treating fungal infections with amphotericin B/cholesterol sulfate composition |
| US4994213A (en) | 1988-05-17 | 1991-02-19 | Liposome Technology, Inc. | Method of preparing lipid structures |
| US5082866A (en) | 1988-06-01 | 1992-01-21 | Odontex, Inc. | Biodegradable absorption enhancers |
| US4980378A (en) | 1988-06-01 | 1990-12-25 | Odontex, Inc. | Biodegradable absorption enhancers |
| US5194581A (en) | 1989-03-09 | 1993-03-16 | Leong Kam W | Biodegradable poly(phosphoesters) |
| US5194266A (en) | 1989-08-08 | 1993-03-16 | Liposome Technology, Inc. | Amphotericin B/cholesterol sulfate composition and method |
| US5356633A (en) | 1989-10-20 | 1994-10-18 | Liposome Technology, Inc. | Method of treatment of inflamed tissues |
| DE69211691T2 (de) | 1991-04-19 | 1997-01-16 | Nexstar Pharmaceuticals Inc., Boulder, Col. | Pharmazeutische formulierung und pharmazeutisches verfahren |
| US5176907A (en) | 1991-08-13 | 1993-01-05 | The Johns Hopkins University School Of Medicine | Biocompatible and biodegradable poly (phosphoester-urethanes) |
| GR1002207B (en) | 1992-08-06 | 1996-03-27 | Johnson & Johnson Consumer | Skin care compositions containing imidazoles. |
| US5552155A (en) | 1992-12-04 | 1996-09-03 | The Liposome Company, Inc. | Fusogenic lipsomes and methods for making and using same |
| US5480971A (en) * | 1993-06-17 | 1996-01-02 | Houghten Pharmaceuticals, Inc. | Peralkylated oligopeptide mixtures |
| US6051576A (en) | 1994-01-28 | 2000-04-18 | University Of Kentucky Research Foundation | Means to achieve sustained release of synergistic drugs by conjugation |
| US5591317A (en) | 1994-02-16 | 1997-01-07 | Pitts, Jr.; M. Michael | Electrostatic device for water treatment |
| US5716622A (en) | 1995-01-06 | 1998-02-10 | The Rockefeller University | Functionally active regions of signal transducer and activators of transcription |
| US5783683A (en) | 1995-01-10 | 1998-07-21 | Genta Inc. | Antisense oligonucleotides which reduce expression of the FGFRI gene |
| AU5938996A (en) | 1995-06-07 | 1996-12-30 | Nexstar Pharmaceuticals, Inc. | Method for encapsulating pharmaceutical materials |
| US5747470A (en) | 1995-06-07 | 1998-05-05 | Gen-Probe Incorporated | Method for inhibiting cellular proliferation using antisense oligonucleotides to gp130 mRNA |
| US6413961B1 (en) | 1995-12-12 | 2002-07-02 | Omeros Medical Systems, Inc. | Irrigation solution and method for inhibition of pain and inflammation |
| SE508357C2 (sv) | 1996-01-02 | 1998-09-28 | Kay Laserow | Mätinstrument för mätning av smärta jämte ett förfarande för att med ett mätinstrument mäta smärta |
| WO1998024428A1 (en) | 1996-12-02 | 1998-06-11 | Brigham & Women's Hospital, Inc. | Long-acting local anesthetics |
| SE9604751D0 (sv) | 1996-12-20 | 1996-12-20 | Astra Ab | New therapy |
| US5837713A (en) * | 1997-02-26 | 1998-11-17 | Mayo Foundation For Medical Education And Research | Treatment of eosinophil-associated pathologies by administration of topical anesthetics and glucocorticoids |
| EP0991699B1 (en) | 1997-06-18 | 2002-04-24 | Guilford Pharmaceuticals Inc. | Two-stage solution polymerization of high molecular weight poly(phosphoesters) |
| US6028163A (en) | 1997-06-27 | 2000-02-22 | Guilford Pharmaceuticals Inc. | Solution polymerization of high molecular weight poly(phosphoesters) in toluene |
| EP0997147B1 (en) | 1997-07-08 | 2006-03-15 | Ono Pharmaceutical Co., Ltd. | Amino acid derivatives |
| TW536401B (en) | 1997-09-03 | 2003-06-11 | Cardiome Pharma Corp | A pharmaceutical composition of N,N-bis(phenylcarbamoylmethyl)dimethylammomum chloride and derivatives for the treatment of pain |
| US6623040B1 (en) | 1997-09-03 | 2003-09-23 | Recot, Inc. | Method for determining forced choice consumer preferences by hedonic testing |
| US6083996A (en) | 1997-11-05 | 2000-07-04 | Nexmed Holdings, Inc. | Topical compositions for NSAI drug delivery |
| KR20010072593A (ko) | 1998-06-09 | 2001-07-31 | 추후보정 | 기침 치료용 조성물 및 기침 치료방법 |
| US6153212A (en) | 1998-10-02 | 2000-11-28 | Guilford Pharmaceuticals Inc. | Biodegradable terephthalate polyester-poly (phosphonate) compositions, articles, and methods of using the same |
| US6103255A (en) | 1999-04-16 | 2000-08-15 | Rutgers, The State University | Porous polymer scaffolds for tissue engineering |
| US6118020A (en) | 1999-05-19 | 2000-09-12 | Nexmed Holdings, Inc. | Crystalline salts of dodecyl 2-(N,N-dimethylamino)-propionate |
| WO2001025234A1 (en) * | 1999-10-01 | 2001-04-12 | Advanced Medicine, Inc. | Quinazolinones and analogues and their use as local anesthetics |
| AU2334501A (en) * | 1999-12-15 | 2001-06-25 | Ucb Farchim Sa | Cyclic quaternary ammonium compounds |
| WO2001044218A1 (en) | 1999-12-15 | 2001-06-21 | Ucb Farchim S.A. | Quaternary salts of n-substituted cyclic or acyclic amines as pharmaceuticals |
| WO2001045678A2 (de) | 1999-12-21 | 2001-06-28 | Id Pharma Gmbh | Arzneimittel, verfahren zu dessen herstellung und dessen verwendung |
| WO2001083828A1 (en) | 2000-05-04 | 2001-11-08 | Dzgenes, Llc | TGFβ-RII PROMOTER POLYMORPHISMS |
| WO2002000218A2 (en) * | 2000-06-23 | 2002-01-03 | Mayo Foundation For Medical Education And Research | Methods of treating neutrophil-related diseases with topical anesthetics |
| DE10039449A1 (de) | 2000-08-11 | 2003-07-24 | Id Pharma Gmbh I Ins | Verwendung einer lokalanästhetikumhaltigen Zusammensetzung zur Behandlung von Hyperalgesien |
| US6766319B1 (en) | 2000-10-31 | 2004-07-20 | Robert J. Might | Method and apparatus for gathering and evaluating information |
| US6884782B2 (en) | 2000-11-08 | 2005-04-26 | Amgen Inc. | STAT modulators |
| US20030152637A1 (en) | 2001-01-25 | 2003-08-14 | Mark Chasin | Local anesthetic, and method of use |
| US20040146590A1 (en) | 2001-03-22 | 2004-07-29 | Iadarola Michael J | Molecular neurochirurgie for pain control administering locally capsaicin or resinferatoxin |
| US20030027833A1 (en) | 2001-05-07 | 2003-02-06 | Cleary Gary W. | Compositions and delivery systems for administration of a local anesthetic agent |
| EP1399440B1 (en) | 2001-06-15 | 2009-06-03 | Vertex Pharmaceuticals Incorporated | 5-(2-aminopyrimidin-4-yl)benzisoxazoles as protein kinase inhibitors |
| ITMI20012025A1 (it) | 2001-09-28 | 2003-03-28 | Dompe Spa | Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono |
| AU2003254426A1 (en) | 2002-08-02 | 2004-02-23 | Universite Libre De Bruxelles | Apolipoprotein l-i for the treatment or diagnosis of prypanosomaldiseases |
| EA012599B1 (ru) | 2003-04-10 | 2009-10-30 | Ньюроджескс, Инк. | Способы и композиции для введения агонистов trpv1 |
| US20040220187A1 (en) * | 2003-04-22 | 2004-11-04 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a sodium ion channel blocker for the treatment of pain, inflammation or inflammation mediated disorders |
| WO2004093813A2 (en) | 2003-04-22 | 2004-11-04 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders |
| ES2223277B1 (es) | 2003-06-19 | 2006-03-01 | Fernando Bouffard Fita | Composicion anestesica para administracion topica. |
| US8361467B2 (en) | 2003-07-30 | 2013-01-29 | Depuy Spine, Inc. | Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints |
| NO20034069L (no) | 2003-09-12 | 2005-03-14 | Aximed As | Fremstilling og bruk av capsaicinderivater |
| US20070149469A1 (en) | 2003-10-02 | 2007-06-28 | Christian Korherr | Medical use of tbk-1 or of inhibitors thereof |
| US20050142596A1 (en) | 2003-11-14 | 2005-06-30 | Krolewski Andrzej S. | Methods of diagnosing renal and cardiovascular disease |
| PT1701941E (pt) | 2003-12-11 | 2012-08-03 | Univ Texas | Compostos para o tratamento de doenças proliferativas celulares |
| US20070196866A1 (en) | 2004-03-13 | 2007-08-23 | Irm Llc | Modulators of ion channel trpa1 |
| US7161034B2 (en) | 2004-04-20 | 2007-01-09 | Dade Behring Inc. | Lidocaine analogs and methods of making and using same |
| WO2005105814A1 (en) | 2004-04-28 | 2005-11-10 | Incyte Corporation | Tetracyclic inhibitors of janus kinases |
| ES2542847T3 (es) | 2004-06-02 | 2015-08-12 | Neurogesx Inc. | Formulaciones que comprenden capsaicina, un anestésico local y/o un agente antipruriginoso para el tratamiento del dolor |
| ES2651021T3 (es) | 2004-07-24 | 2018-01-23 | Laboratorios Del Dr. Esteve, S.A. | Uso de compuestos activos sobre el receptor sigma para el tratamiento de alodinia mecánica |
| ITMI20041566A1 (it) | 2004-07-30 | 2004-10-30 | Indena Spa | "trpv1 agonisti, formulazioni che li contengono e loro usi" |
| WO2006036180A1 (en) * | 2004-09-20 | 2006-04-06 | Corus Pharma, Inc. | Targeted delivery of lidocaine and other local anesthetics and a method for treatment of cough and tussive attacks |
| US7947682B2 (en) | 2004-12-29 | 2011-05-24 | University Of Southern California | Substituted N′-pyrrolo[1,2-a]quinoxalin-4-yl-hydrazides as anti-cancer agents |
| US20060134008A1 (en) | 2004-12-16 | 2006-06-22 | Daniel Deaver | Compositions and methods for pulmonary conditions |
| AR054416A1 (es) | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
| US20070149506A1 (en) | 2005-09-22 | 2007-06-28 | Arvanitis Argyrios G | Azepine inhibitors of Janus kinases |
| ES2542989T3 (es) | 2005-10-12 | 2015-08-13 | Idera Pharmaceuticals, Inc. | Compuestos oligonucleótidos inmuno reguladores (IRO) para modular la respuesta inmune basada en receptor semejante a Toll |
| KR101391900B1 (ko) | 2005-12-13 | 2014-05-02 | 인사이트 코포레이션 | 야누스 키나아제 억제제로서의 헤테로아릴 치환된 피롤로［2,3-ｂ］피리딘 및 피롤로［2,3-ｂ］피리미딘 |
| AU2006329202A1 (en) | 2005-12-21 | 2007-06-28 | Painceptor Pharma Corporation | Compositions and methods for modulating gated ion channels |
| GB0526244D0 (en) * | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
| EP1867338A1 (en) | 2006-05-30 | 2007-12-19 | Université Libre De Bruxelles | Pharmaceutical composition comprising apolipoproteins for the treatment of human diseases |
| JP2010510227A (ja) * | 2006-11-20 | 2010-04-02 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | 痛みおよび痒みの治療方法、組成物およびキット |
| EP2121692B1 (en) | 2006-12-22 | 2013-04-10 | Incyte Corporation | Substituted heterocycles as janus kinase inhibitors |
| WO2009026107A1 (en) | 2007-08-17 | 2009-02-26 | Portola Pharmaceuticals, Inc. | Protein kinase inhibitors |
| CN101156851A (zh) * | 2007-09-27 | 2008-04-09 | 刘全胜 | 盐酸尼卡地平分散片及其制备方法 |
| CA2717042A1 (en) | 2008-03-11 | 2009-09-17 | The General Hospital Corporation | Methods, compositions, and kits for treating pain and pruritis |
| US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| US8258144B2 (en) | 2008-04-22 | 2012-09-04 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| NZ590372A (en) | 2008-07-08 | 2012-09-28 | Univ Texas | Novel inhibitors of proliferation and activation of signal transducer and activator of transcription (stats) |
| DE102008037682A1 (de) * | 2008-08-14 | 2010-04-08 | Strackharn, Klaus, Dr.med. | Verwendung äquipotenter Dosierungen von Lokalanästetika oder Derivaten davon zur Therapie chronischer Schmerzen |
| CN101347427A (zh) * | 2008-09-22 | 2009-01-21 | 北京理工大学 | 一种沙坦化合物或其可药用盐和钙通道阻断剂或可药用盐的复方 |
| CL2009001884A1 (es) | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
| KR20110071108A (ko) | 2008-10-06 | 2011-06-28 | 이데라 파마슈티칼즈, 인코포레이티드 | 고콜레스테롤혈증 및 고지혈증 및 이에 관련된 질병의 예방 및 치료에서 톨-유사 수용체의 저해제의 용도 |
| WO2010111471A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| JP6205133B2 (ja) | 2009-07-10 | 2017-09-27 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 抗炎症剤としての恒久的に荷電したナトリウムおよびカルシウムチャンネルブロッカー |
| US9023355B2 (en) | 2010-04-13 | 2015-05-05 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for treating renal disease |
| US9828637B2 (en) | 2010-04-18 | 2017-11-28 | Wake Forest University Health Sciences | Methods of predicting predisposition to or risk of kidney disease |
| WO2012030912A1 (en) | 2010-09-01 | 2012-03-08 | Ambit Biosciences Corporation | 7-cyclylquinazoline derivatives and methods of use thereof |
| US8822537B2 (en) | 2012-09-27 | 2014-09-02 | Achelios Therapeutics, Inc. | Topical ketoprofen composition |
| RU2018107695A (ru) | 2015-08-03 | 2019-09-05 | Президент Энд Феллоуз Оф Гарвард Колледж | Заряженные блокаторы ионных каналов и способы их применения |
-
2010
- 2010-07-09 JP JP2012519763A patent/JP6205133B2/ja not_active Expired - Fee Related
- 2010-07-09 WO PCT/US2010/041537 patent/WO2011006073A1/en not_active Ceased
- 2010-07-09 US US13/382,834 patent/US20120172429A1/en not_active Abandoned
- 2010-07-09 CN CN2010800408307A patent/CN102725401A/zh active Pending
- 2010-07-09 EP EP10797919A patent/EP2451944A4/en not_active Ceased
- 2010-07-09 EP EP15002768.8A patent/EP2995303A1/en not_active Withdrawn
- 2010-07-09 CA CA2767646A patent/CA2767646C/en not_active Expired - Fee Related
- 2010-07-09 AU AU2010271269A patent/AU2010271269B2/en not_active Ceased
- 2010-07-09 CA CA3027255A patent/CA3027255C/en active Active
- 2010-07-09 EP EP18211462.9A patent/EP3485881B1/en active Active
-
2016
- 2016-11-23 AU AU2016262678A patent/AU2016262678A1/en not_active Abandoned
-
2017
- 2017-04-25 JP JP2017086446A patent/JP6530005B2/ja not_active Expired - Fee Related
-
2018
- 2018-10-01 AU AU2018236902A patent/AU2018236902B2/en active Active
- 2018-12-11 US US16/216,489 patent/US10729664B2/en active Active
-
2019
- 2019-05-15 JP JP2019091784A patent/JP6845280B2/ja active Active
-
2020
- 2020-03-09 US US16/813,624 patent/US20210030695A1/en not_active Abandoned
- 2020-09-21 AU AU2020239616A patent/AU2020239616A1/en not_active Abandoned
-
2021
- 2021-02-25 JP JP2021028224A patent/JP2021098713A/ja active Pending
- 2021-06-02 US US17/337,149 patent/US20210290561A1/en not_active Abandoned
- 2021-09-17 US US17/477,749 patent/US20220016046A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012532887A5 (enExample) | ||
| JP2011513484A5 (enExample) | ||
| Trivedi et al. | Design, synthesis and biological screening of 2-aminobenzamides as selective HDAC3 inhibitors with promising anticancer effects | |
| US9265734B2 (en) | Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors | |
| SA522433000B1 (ar) | مركبات فلورو ألكيل-أوكساديازول واستخداماتها | |
| JP2022120072A (ja) | ヒストンアセチルトランスフェラーゼ活性化剤及び組成物並びにそれらの使用 | |
| JP2009544602A5 (enExample) | ||
| PE20040802A1 (es) | Derivados de 3-(3,5-dioxo-4,5-dihidro-3h-[1,2,4]-triazin-2-il)-benzamidas como inhibidores del receptor p2x7 | |
| TW200519084A (en) | Cyclic amine bace-1 inhibitors having a benzamide substituent | |
| AR068512A1 (es) | Derivados de 4-aril-1h-piridin-2-onas disustituidas, composiciones farmaceuticas que las contienen y usos de las mismas para tratar o prevenir trastornos del sistema nervioso central | |
| AR062176A1 (es) | Derivados de nicotinamida, una composicion farmaceutica que los comprende y su uso para tratar enfermedades asociadas con miosina de musculo liso o miosina no muscular | |
| NO20081582L (no) | Benzamidforbindelser anvendbare som histon-deacetylaseinhibitorer | |
| CL2008003651A1 (es) | Compuestos derivados de 3,5-diamino-6-cloropirazinamida sustituida; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de una condición inflamatoria o alergica, en particular una enfermedad inflamatoria u obstructiva de las vias respiratorias. | |
| BRPI0017535B1 (pt) | Composto de difenil-uréias substituídas com ?- carbóxi-arilas | |
| JP2011529037A5 (enExample) | ||
| EP4054559A1 (en) | Charged ion channel blockers and methods for use | |
| CL2023000223A1 (es) | Nuevos inhibidores selectivos de hdac6 basados en oxadiazol | |
| JP2016516716A (ja) | Ｈｄａｃ阻害剤 | |
| JP2019510025A5 (enExample) | ||
| CA2667387A1 (en) | New benzamide derivatives as bradykinin antagonists | |
| JP2022554359A (ja) | ホスホニウムイオンチャンネル遮断薬および使用方法 | |
| AR078856A1 (es) | Composiciones locales de emulsion anestesica y metodos para la fabricacion y utilizacion de las mismas | |
| WO2021091586A1 (en) | Charged ion channel blockers and methods for use | |
| RU2008144952A (ru) | Производные аминометилпиридина, их получение и их применение в терапии | |
| EA202190077A1 (ru) | Ингибиторы гистондеацетилазы |